KYMERA THERAPEUTICS, INC. (KYMR) FY2026 Q3 Statement of Cash Flows

Published Source: Form 10-Q on SEC EDGAR filed (opens in a new tab)

2026-07-01 to 2026-09-30

Statement of Cash Flows

Swipe to see the full flow
KYMERA THERAPEUTICS, INC. cash flow reconciliation, Jul 1, 2026 through Sep 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Intermediate calculation bars are lighter gray. Calculated remaining financing cash flows are purple; remaining operating and investing bundles are gray. Their underlying inflows and outflows are not separately identified. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Issuance of common stock through at-the-market sales agreement, net of issuance costs of $4.5 million → financing reconciliation: $215,392,000.00Proceeds from stock option exercises → financing reconciliation: $10,618,000.00financing reconciliation → Net cash from financing activities: $225,566,000.00financing reconciliation → Payments on finance leases: $444,000.00Maturities of investments → investing reconciliation: $162,601,000.00investing reconciliation → Net cash from investing activities: $101,631,000.00investing reconciliation → Purchases of investments: $60,655,000.00investing reconciliation → Purchase of property and equipment, net: $315,000.00Net cash used in operating activities → operating reconciliation: $77,913,000.00Remaining operating cash flows, net (calculated) → operating reconciliation: $20,000,000.00Stock-based compensation expense → operating reconciliation: $18,837,000.00Accrued expenses and other current liabilities → operating reconciliation: $14,839,000.00Accounts payable → operating reconciliation: $3,025,000.00Depreciation and amortization → operating reconciliation: $2,023,000.00Operating lease right-of-use assets → operating reconciliation: $656,000.00Other assets and liabilities → operating reconciliation: $654,000.00operating reconciliation → Net loss: $131,999,000.00operating reconciliation → Other long term assets: $1,728,000.00operating reconciliation → Premiums and discounts on available-for-sale marketable securities: $1,607,000.00operating reconciliation → Operating lease liabilities: $1,515,000.00operating reconciliation → Prepaid expenses and other current assets: $1,098,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations → Cash sources and uses: $130,299,000.00Net cash from financing activities → Cash sources and uses: $225,566,000.00Net cash from investing activities → Cash sources and uses: $101,631,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $379,583,000.00Cash sources and uses → Net cash used in operating activities: $77,913,000.00Net loss: -$131,999,000.00Net loss−$132.00 MStock-based compensation expense: $18,837,000.00Stock-based compensation+$18.84 MDepreciation and amortization: $2,023,000.00Depreciation & amortization+$2.02 MPremiums and discounts on available-for-sale marketable securities: -$1,607,000.00Premiums and discounts on available-for-salemarketable securities−$1.61 MPrepaid expenses and other current assets: -$1,098,000.00Prepaid & other assets−$1.10 MContract asset: -$0.00Other long term assets: -$1,728,000.00Other noncurrent assets−$1.73 MAccounts payable: $3,025,000.00Accounts payable+$3.03 MAccrued expenses and other current liabilities: $14,839,000.00Accrued liabilities+$14.84 MDeferred revenue: $0.00Operating lease right-of-use assets: $656,000.00Operating lease right-of-use assets+$656.00 KOperating lease liabilities: -$1,515,000.00Operating lease liabilities−$1.52 MOther assets and liabilities: $654,000.00Other working capital, net+$654.00 KRemaining operating cash flows, net (calculated): $20,000,000.00Remaining operating (calculated)+$20.00 MNet cash used in operating activities: -$77,913,000.00. Cash required to fund net payments.Operating cash−$77.91 Moperating reconciliation: $137,947,000.00Issuance of common stock and accompanying pre-funded warrants from June 2025 public offering, net of issuance costs of $15.7 million: $0.00Issuance of common stock through at-the-market sales agreement, net of issuance costs of $4.5 million: $215,392,000.00Stock option exercises+$215.39 MProceeds from stock option exercises: $10,618,000.00Stock plan proceeds+$10.62 MProceeds from employee stock purchase plan: $0.00Payments on finance leases: -$444,000.00Financing costs paid−$444.00 KNet cash from financing activities: $225,566,000.00Financing cash+$225.57 Mfinancing reconciliation: $226,010,000.00Purchase of property and equipment, net: -$315,000.00PP&E purchases−$315.00 KPurchases of investments: -$60,655,000.00Investment purchases−$60.66 MMaturities of investments: $162,601,000.00Investment sales & maturities+$162.60 MNet cash from investing activities: $101,631,000.00Investing cash+$101.63 Minvesting reconciliation: $162,601,000.00Cash sources and uses: $457,496,000.00Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $130,299,000.00Beginning cash$130.30 MEnding cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations: $379,583,000.00Ending cash$379.58 MCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsNet loss −$132.00M + net operating adjustments $54.09M = operating cash −$77.91MFree cash flow−$78.23 MOperating cash − cash spent on PP&ECash flow / Net incomeNot meaningfulOperating cash flow ÷ net incomeNet cash change+$249.28 MEnding cash − beginning cash
Chart details

KYMERA THERAPEUTICS, INC. cash flow reconciliation, Jul 1, 2026 through Sep 30, 2026

Cash flows for Jul 1, 2026 through Sep 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations. Beginning cash: Jun 30, 2026. Ending cash: Sep 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Jun 30, 2026
130,299,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Operating activities
negative 77,913,000 US dollars. Net cash used. The remaining amount is calculated by subtracting the other displayed items from the operating total. This quarter is the year to date less the prior quarter's year to date. The prior quarter reported part of this section under different lines (Accounts receivable), so Lease impairment charge cannot be separated for this quarter. It may combine inflows and outflows.
Net loss
negative 131,999,000 US dollars
Stock-based compensation expense
18,837,000 US dollars
Depreciation and amortization
2,023,000 US dollars
Premiums and discounts on available-for-sale marketable securities
negative 1,607,000 US dollars
Prepaid expenses and other current assets
negative 1,098,000 US dollars
Contract asset
0 US dollars
Other long term assets
negative 1,728,000 US dollars
Accounts payable
3,025,000 US dollars
Accrued expenses and other current liabilities
14,839,000 US dollars
Deferred revenue
0 US dollars
Operating lease right-of-use assets
656,000 US dollars
Operating lease liabilities
negative 1,515,000 US dollars
Other assets and liabilities
654,000 US dollars
Remaining operating cash flows, net (calculated)
20,000,000 US dollars
Investing activities
101,631,000 US dollars. Net cash provided.
Purchase of property and equipment, net
negative 315,000 US dollars
Purchases of investments
negative 60,655,000 US dollars
Maturities of investments
162,601,000 US dollars
Financing activities
225,566,000 US dollars. Net cash provided.
Issuance of common stock and accompanying pre-funded warrants from June 2025 public offering, net of issuance costs of $15.7 million
0 US dollars
Issuance of common stock through at-the-market sales agreement, net of issuance costs of $4.5 million
215,392,000 US dollars
Proceeds from stock option exercises
10,618,000 US dollars
Proceeds from employee stock purchase plan
0 US dollars
Payments on finance leases
negative 444,000 US dollars
Operating adjustment reconciliation
137,947,000 US dollars. Intermediate calculation joining the displayed items and the calculated net remainder. It does not establish gross cash receipts or payments and is not an additional cash flow.
financing gross reconciliation
226,010,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
162,601,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
0 US dollars
Ending cash on Sep 30, 2026
379,583,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash, including disposal groups and discontinued operations
Cash sources and uses
457,496,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
249,284,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
Not meaningful. Operating cash flow divided by reconciliation net income for the same period. The ratio is not meaningful when net income is zero or negative.
Operating cash flow
negative 77,913,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
315,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 78,228,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net loss −$132.00M + net operating adjustments $54.09M = operating cash −$77.91M. The loss reduces the earnings basis of the reconciliation; it is not a cash payment. The signed loss remains a deduction at the operating reconciliation junction.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 77,913,000 US dollars minus 315,000 US dollars equals negative 78,228,000 US dollars.
KYMERA THERAPEUTICS, INC. (KYMR) FY2026 Q3 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!